ClinicalTrials.gg
Not yet recruitingNCT07940569GLUT-5 SCDUpdated Nov 17, 2026

Glutamine Early Start in Children With SCD Younger Than Five

A Phase 3 interventional study of Glutamine and Standard of Care (SOC) in Sickle Cell Disease (SCD), sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 1 Year to 5 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ain Shams University · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
1 Year to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Anemia, Sickle Cell with a site in Egypt — 9 open to participants now, 10 under way, 3 of them phase 3. Anemia, Sickle Cell · Egypt.

Planned enrollment
20th of 29
70 · median 91
Started
2026
with 1 other
Phase 3
11 of 33
2 open now
Registered
33rd of 33
by date
Lead sponsor
5 of 33
Ain Shams University

Among the 33 studies in Anemia, Sickle Cell with a site in Egypt, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 in phase 3, and was the 33rd registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

9 of the 33 studies in Anemia, Sickle Cell with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Anemia, Sickle Cell with a site in Egypt, or all of them as a file.
02

Study summary

A study to assess the efficacy and safety of Glutamine in preventing Vaso Occlusive Crisis in pediatric population less than five years old

03

Conditions studied

  • Sickle Cell Disease (SCD)

Browse trials for

Keywords

  • Sickle cell disease
  • Glutamine
04

Who can participate

Ages eligible
1 Year to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 1-5 years
  • children diagnosed with SCD based on clinical picture, CBC, reticulocyte count, markers of hemolysis and analysis by HPLC

Exclusion criteria

Exclusion Criteria:

  • Patients with renal or liver disease
  • Patients with any clinical evidence of infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Patients receiving standard of care

    Other: Standard of Care (SOC)

  • Experimental
    Patients receiving Glutamine

    Drug: Glutamine · Other: Standard of Care (SOC)

Interventions

  • DrugGlutamine

    L-Glutamine as an oral powder

  • OtherStandard of Care (SOC)

    Standard of care in SCD therapy as Hydroxyurea

06

What researchers measure

Primary outcomes

  1. Assessment of safety of L-Glutamine in children with SCD younger than 5 years old

    Assessment of safety of L-Glutamine in children with SCD younger than 5 years old by assessing the adverse event

    Time frame: 52 weeks

Secondary outcomes

  1. Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs

    Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs from baseline to week 52

    Time frame: 52 weeks

07

Study locations

1 site
  • Faculty of Medicine Ain Shams Research Institute- Clinical Research Center
    Cairo, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 35 phase 3 interventional studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 61. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940569
Responsible party
Fatma Soliman Elsayed Ebeid, MD (Professor of pediatric hematology, oncology and BMT, Ain Shams University) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Fatma S Ebeid, MD
Contact
fatmaebeid@med.asu.edu.eg
+201095569596
Nihal H Aly, MD
Contact
+201001053961
Fatma SE Ebeid, MD
principal investigator · Faculty of Medicine Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion